| Document |
Document Title |
|
WO/2020/081971A1 |
The present disclosure provides a method for treating a cancer or refractory caner and/or inhibiting cancer metastasis, recurrence or progression in a subject or increasing the likelihood of survival over a relevant period in a subject d...
|
|
WO/2020/076123A1 |
The present invention relates to a compound, a photoresist composition comprising same, a photoresist pattern comprising same, and a method for manufacturing a photoresist pattern.
|
|
WO/2020/069056A1 |
Disclosed is a compound of Formula I, including N-oxides, and salts thereof, wherein R1, R2 and R3 are defined as set forth in the disclosure. Also disclosed is a process for preparing a compound of Formula I. A compound of Formula I can...
|
|
WO/2020/069418A1 |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazi...
|
|
WO/2020/069057A1 |
Disclosed are compounds of Formula I and N-oxides or salts thereof, wherein R1 is C1-C4alkyl or C3-C6cycloalkyl; R2 is H, Cl, Br or I; R3 is Cl or OR4; R4 is H or C1-C4 alkyl; R5 is H, F, Cl or CH3; and R6 is H or Cl. Also disclosed is a...
|
|
WO/2020/069402A1 |
Cinnoline compounds of formula (I), variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also desc...
|
|
WO/2020/061473A1 |
Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with a mutation in a protein. One aspect of the invention provides compounds, compositions, and methods useful for trea...
|
|
WO/2020/057391A1 |
Provided is a pyridazinyl amine compound with broad-spectrum herbicidal activity and having a structure represented by general formula (I). The definition of each substituent in the formula is described in the description. The compound h...
|
|
WO/2020/061476A1 |
Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with mutation in a protein. One aspect of the invention provides compounds, compositions, and methods useful for treati...
|
|
WO/2020/051099A1 |
The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as...
|
|
WO/2020/051207A2 |
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...
|
|
WO/2020/047651A1 |
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and poly-(ADP-ribose) polymerase (PARP) inhibitor. The CD47 blocking agent can be SIRPαFc and the PARP inhibitor niraparib. The anti-cancer ...
|
|
WO/2020/041180A1 |
A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives. The one or more solubilizing and/or stabilizing agents may be a cyclodextrin or ...
|
|
WO/2020/038405A1 |
Provided are a preparation method of pyrrolo-amino-pyridazinone compound and an intermediate thereof. The reaction conditions are easy to control, the processing following the reaction is simple, the production rate is high, and the meth...
|
|
WO/2020/022470A1 |
The present invention provide a compound which has excellent ATX inhibitory activity and is thus useful for prophylaxis or treatment of diseases associated with ATX. A carboxylic acid compound which is represented by general formula (1) ...
|
|
WO/2020/017587A1 |
Provided are: a pyridazinone derivative and/or a pharmaceutically acceptable salt thereof, which is useful as a therapeutic agent and/or a prophylactic agent for diseases in which Nav1.1 is involved and various central nervous system dis...
|
|
WO/2020/014243A1 |
Pyridazine compounds for inhibiting NaV1.8 and methods for treating a condition, disease, or disorder associated with an increased NaV1.8 activity or expression are disclosed.
|
|
WO/2020/003298A1 |
The present invention is directed to a polymer comprising a first hyaluronic acid (HA) chain and a second HA chain crosslinked via a linker comprising an unsaturated moiety or a derivative thereof coupled to a tetrazine moiety or a deriv...
|
|
WO/2019/233209A1 |
A catalyst and a method for preparing S-indoxacarb using the catalyst. The catalyst is prepared using 3-tert-butyl-5-chloromethyl salicylaldehyde and cyclohexanediamine as raw materials, where an original quinine catalyst such as cinchon...
|
|
WO/2019/236625A1 |
Disclosed are compounds that activate excitatory amino acid transporter 2 (EAAT2), as well as methods of using these compounds to treat or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.
|
|
WO/2019/236879A1 |
The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing neurodegenerative disease or axonal degeneration. The provided SARM1 inhibitors may reduce or inhibit binding of NAD+ by ...
|
|
WO/2019/237076A1 |
Provided herein are methods, compositions, and kits for inhibiting NMD of mRNA transcribed from a gene comprising one or more nonsense mutations and for treating conditions associated with the presence of said one or more nonsense mutati...
|
|
WO/2019/226820A1 |
Disclosed herein are GABAA positive allosteric modulators for the treatment of pruritic conditions and dermatitis. Also disclosed herein are formulations comprising the GABAA positive allosteric modulators.
|
|
WO/2019/202607A1 |
The present invention relates to a compound of formula I, wherein R is selected from the group consisting of -H, -F, -Cl, -Br, -I, -NO2, -CH3, and -C2H5; X is selected from the group consisting of -F, -Cl, -Br, and –I; and pharmaceutic...
|
|
WO/2019/200120A1 |
The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.
|
|
WO/2019/185932A1 |
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises...
|
|
WO/2019/185933A1 |
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is amenable to automation. In particular, the method of the present invention comprises a method...
|
|
WO/2019/186135A1 |
The present invention relates to radiolabelled olaparib and in particular [ 18 F]olaparib, a process for producing radiolabelled olaparib, and uses of radiolabelled olaparib in medical imaging.
|
|
WO/2019/175149A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2019/169156A1 |
The present disclosure provides compounds of Formula (I) or (II), pharmaceutically acceptable salt, isotopic variant, stereoisomer, or a mixture thereof. Also provided are pharmaceutical compositions comprising a compound, methods of tre...
|
|
WO/2019/165158A1 |
The instant invention describes compounds having IL-6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by IL-6.
|
|
WO/2019/161162A1 |
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).
|
|
WO/2019/154363A1 |
A compound represented by formula (I) or an isomer or pharmaceutically acceptable salt thereof. The present invention also relates to an application of the same in preparing a drug for treating a disease related to a PGI2 receptor.
|
|
WO/2019/149259A1 |
The present invention relates to a P2Y12 receptor antagonist containing a guanidyl, and a preparation method and the use thereof. In particular, the present invention provides a pyridazinone-guanidine compound that is a compound of struc...
|
|
WO/2019/149260A1 |
The present invention relates to the field of pesticide technology, and specifically discloses a pyridazinol compound as represented by general formula I, a derivative thereof, a preparation method therefor, a herbicidal composition ther...
|
|
WO/2019/144875A1 |
The present invention relates to the technical field of medicinal chemistry, and relates in particular to a phthalazone derivative prodrug or a pharmaceutically acceptable salt thereof, and relates to a pharmaceutical composition thereof...
|
|
WO/2019/144835A1 |
The present invention relates to a pharmaceutical composition of a substituted pyridazinone compound and use thereof. The substituted pyridazinone compound is a compound as represented by formula (I), or a pharmaceutically acceptable sal...
|
|
WO/2019/143757A1 |
Disclosed are compounds of Formula (1), including all stereoisomers, N-oxides, and salts thereof, Formula (1) wherein R1, A, L, R2, R3 and R4 are as defined in the disclosure. Also disclosed are compositions containing the compounds of F...
|
|
WO/2019/142192A1 |
Novel compounds capable of inhibiting methionine metabolic pathway are provided. These compounds are used in inhibiting cystathionin γ-synthase (CGS) in general, and in plants, fungi and bacteria, in particular. These compounds of the i...
|
|
WO/2019/137851A1 |
The present invention relates to herbicidal substituted phenyl-pyridazine-diones and substituted phenyl-pyridazinone derivatives of formula (I), as well as to processes and intermediates used for the preparation of such derivatives. The ...
|
|
WO/2019/137825A1 |
The present invention relates to a method for solubilizing 5-amino-2,3-dihydro-1,4- phthalazinedione or salts thereof, to the solubilisate produced by this method and respective uses in pharmaceutical dosage forms. A phosphatidylcholine-...
|
|
WO/2019/133813A1 |
The present invention provides pyrazoles, isoxazoles, isothiazoles, thiadiazoles, and pyridazines according to Formula I as described herein, and pharmaceutically acceptable salts thereof. Pharmaceutical compositions and methods for trea...
|
|
WO/2019/133635A1 |
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associ...
|
|
WO/2019/115498A1 |
The present invention relates to novel benzamides derivatives of formula (I) as modulators of PPAR-gamma receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use ...
|
|
WO/2019/105234A1 |
The present invention relates to an aromatic compound, a pharmaceutical composition comprising the compound, and a method for preparing the compound and an intermediate thereof. The present invention further relates to use of the compoun...
|
|
WO/2019/101643A1 |
The present invention covers 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine- 4-carboxamide compounds of general formula (I): in which R1, R2, R4, R5, R6, X, Y and Z are as defined herein, methods of preparing said compounds, intermedi...
|
|
WO/2019/101642A1 |
The present invention covers sulphur substituted 3-oxo-2,3-dihydropyridazine-4 carboxamide compounds of general formula (I): (I) in which R1, R2, A, X, Y and Z are as defined herein, methods of preparing said compounds, intermediate comp...
|
|
WO/2019/094732A1 |
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating diseases associated with the binding of CREB to CREB-binding protein (CBP) and...
|
|
WO/2019/090069A1 |
Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/090076A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
